New-generation intense pulsed light appears safe, effective in MGD-related dry eye
A new-generation intense pulsed light (IPL) device (Eyesis) appears effective and safe in improving the symptoms and signs of meibomian gland dysfunction (MGD)-related dry eye when compared to a traditional IPL device (E-Eye), according toa study.
In this multicenter randomized controlled trial, 132 patients with MGD-related dry eye were randomly assigned to the new-generation IPL group or traditional IPL group. Patients received treatment on days 0 and 7, and had Ocular Surface Disease Index (OSDI), tear meniscus height (TMH), tear breakup time (TBUT), corneal fluorescein staining (CFS), Schirmer test, and meibomian gland signs evaluated on days 0, 7, and 14.
No significant deference between groups was found regarding basic information and the new IPL device was found to be non-inferior to the traditional device (P = 0.927).
On days 7 and 14, significant improvements in OSDI, TBUT, Schirmer test, TMH, CFS, and meibomian gland signs were observed in the new treatment group. There were more significant improvements in OSDI, TBUT, Schirmer test, TMH, and meibum quality in the new treatment group compared to the traditional group. Adverse events were similar between the treatment groups.
Reference
Jiang X, Yuan H, Zhang M, et al. The Efficacy and Safety of New-Generation Intense Pulsed Light in the Treatment of Meibomian Gland Dysfunction-Related Dry Eye: A Multicenter, Randomized, Patients-Blind, Parallel-Control, Non-Inferiority Clinical Trial. Ophthalmol Ther. 2022;doi: 10.1007/s40123-022-00556-1. Epub ahead of print. PMID: 35974296.
